

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior listings and versions of claims in this application.

1. (Original) A clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) comprising the DNA nucleotide sequence of SEQ ID NO: 1 encoding for the fusion (F) gene and at least part of the hemagglutinin-neuraminidase (HN) gene.
2. (Previously presented) A pharmaceutical composition for the treatment of cancer comprising as an active ingredient a lentogenic oncolytic strain of Newcastle Disease Virus (NDV).
3. (Previously presented) The pharmaceutical composition according to claim 2 further comprising a suitable carrier.
4. (Previously presented) The composition according to claim 2 wherein the lentogenic strain of NDV is the HUI strain.
5. (Original) The composition according to claim 4 comprising $10^6 - 10^{12}$ EID₅₀ per unit dose.
6. (Original) The composition according to claim 2 further comprising at least one isolated viral glycoprotein having oncolytic activity.
7. (Original) The composition according to claim 6 wherein the at least one viral glycoprotein is from NDV.
8. (Original) The composition according to claim 7 wherein the at least one viral glycoprotein is the F glycoprotein of NDV.
9. (Original) The composition according to claim 7 wherein the at least one viral glycoprotein is the HN glycoprotein of NDV.
10. (Previously presented) The composition according to claim 7 further comprising the F glycoprotein and hemagglutinin-neuraminidase (HN) glycoprotein of NDV.

11. (Previously presented) The composition according to claim 7 wherein the viral glycoprotein is from a velogenic strain of NDV.
12. (Previously presented) The composition according to claim 7 wherein the viral glycoprotein is from a mesogenic strain of NDV.
13. (Previously presented) The composition according to claim 7 wherein the viral glycoprotein is from a lentogenic strain of NDV.
14. (Original) The composition according to claim 13 wherein the lentogenic strain of NDV is the HUI strain.

Claims 15-23 (cancelled)

24. (Original) A method for treating cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 2.
25. (Original) The method of claim 24 wherein the step of administering is selected from intravenous, oral, buccal, intranasal, inhalation, topical application to a mucosal membrane or injection, including intradermal, intrathecal, intracisternal, and intralesional injection.
26. (Previously presented) The method of claim 24 wherein the step of administering comprises locally administering the composition to a tumor or in its vicinity.
27. (Previously presented) The method of claim 24 wherein the composition comprises a lentogenic oncolytic strain of NDV.
28. (Previously presented) The method of claim 27 wherein the lentogenic oncolytic strain of NDV is the HUI strain.
29. (Previously presented) The method of claim 28 wherein the composition comprises $10^6 - 10^{12}$ EID₅₀ per unit dose.

30. (Previously presented) The method of claim 28 wherein the step of administering comprises administering the HUI strain of NDV in a range of 20 EID₅₀/cell to 2000 EID₅₀/cell.

Claims 31-45. (Cancelled)

46. (Previously presented) A method for treating cancer in a patient comprising administering to the patient in need thereof at least one isolated polynucleotide encoding at least one viral polypeptide, an analog or subunit thereof having oncolytic activity.
47. (Currently amended) The method of claim ~~[[45]]~~ 46, wherein the at least one isolated polynucleotide encodes the fusion glycoprotein of Newcastle Disease Virus.
48. (Currently amended) The method of claim ~~[[45]]~~ 46, wherein the at least one isolated polynucleotide encodes the hemagglutinin-neuraminidase glycoprotein of Newcastle Disease Virus.
49. (Currently amended) The method of claim ~~[[45]]~~ 46, wherein a combination of polynucleotides is administered to the patient, wherein the combination includes an isolated polynucleotide encoding the fusion glycoprotein of Newcastle Disease Virus (NDV) and an isolated polynucleotide encoding the hemagglutinin-neuraminidase glycoprotein of NDV.
50. (Currently amended) The method of claim ~~[[45]]~~ 46, which comprises administering to the patient at least one vector that comprises the at least one isolated polynucleotide encoding at least one viral polypeptide, or an analog or subunit thereof having oncolytic activity.
51. (Previously presented) The method of claim 49, wherein the vector is a viral vector.
52. (Previously presented) The method of claim 49, wherein the vector is an expression vector.
53. (Cancelled)

54. (Cancelled)
55. (Currently Amended) A method of making a cancer treatment composition which comprises incorporating in the composition an isolated viral glycoprotein or a subunit or analog thereof having oncolytic activity ~~or of an isolated polynucleotide encoding the same.~~
56. (New) The method according to claim 55 which further comprises incorporating at least one isolated viral glycoprotein having oncolytic activity in the composition.
57. (New) The method according to claim 46 wherein the polynucleotide encoding at least one viral polypeptide, analog or subunit thereof is administered with at least one isolated viral glycoprotein having oncolytic activity.
58. (New) The method according to claim 57 wherein the at least one viral glycoprotein is from NDV.
59. (New) The method according to claim 58 wherein the at least one viral glycoprotein is the F glycoprotein of NDV.
60. (New) The method according to claim 58 wherein the at least one viral glycoprotein is the HN glycoprotein of NDV.
61. (New) The method according to claim 58 further comprising the F glycoprotein and hemagglutinin-neuraminidase (HN) glycoprotein of NDV.
62. (New) The method according to claim 58 wherein the viral glycoprotein is from a velogenic strain of NDV.
63. (New) The method according to claim 58 wherein the viral glycoprotein is from a mesogenic strain of NDV.
64. (New) The method according to claim 58 wherein the viral glycoprotein is from a lentogenic strain of NDV.
65. (New) The method according to claim 64 wherein the lentogenic strain of NDV is the HUI strain.